← Leaderboards
H. Kirk Hammond
University Of California San Diego
$20,059,661
Attributed
$20,059,661
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $5.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$54,867,804 · 9
VA$0 · 3
By mechanism
P01$47,006,940 · 5
R01$4,175,201 · 2
R42$3,685,663 · 2
I01$0 · 2
IS1$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California San Diego
Same institution · by research overlap
- Wolfgang H Dillmann$17,750,136
- Michael C Hogan$10,116,233
- Gianluigi Condorelli$2,255,321
- Andrew D. McCulloch$21,376,228
- Paul A Insel$35,083,615
Others in their field
Top investigators on “Gene Transfer”
- David Heimbrook · Leidos Biomedical Research, Inc.$217,080,250
- Jeffrey P Krischer · University Of South Florida$141,198,102
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$72,179,157
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$51,608,818
- Keri Hammel · The Emmes Company, Llc$47,641,358
Research focus
Gene TransferHeartClinical TrialsVectorCardiacHeart FailureLaboratoriesHeart FunctionSafetyVirusCardiac MyocytesDesignTransgene ExpressionBiodistributionProteinsExpression VectorCongestive Heart FailurePreclinical StudyVentricularCardiovascular SystemAwardAdeno-Associated Viral VectorIntravenousBase
Grant awards (73)
Urocortin 2 Gene Transfer for Heart Failure with Preserved Ejection Fraction$0
I01 · FY2025 · VA · contact PI
Urocortin 2 Gene Transfer for Heart Failure with Preserved Ejection Fraction$0
I01 · FY2024 · VA · contact PI
Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction$792,556
R42 · FY2023 · HL · contact PI
Urocortin 2 Gene Transfer for Heart Failure with Preserved Ejection Fraction$0
I01 · FY2023 · VA · contact PI
Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction$805,659
R42 · FY2022 · HL · contact PI
Urocortin 2 Gene Transfer for Heart Failure with Preserved Ejection Fraction$0
I01 · FY2022 · VA · contact PI
Urocortin 2 Gene Transfer for Heart Failure with Preserved Ejection Fraction$0
I01 · FY2021 · VA · contact PI
Gene Transfer To Treat Heart Failure With Preserved Ejection Fraction$0
I01 · FY2020 · VA · contact PI
Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction$241,698
R42 · FY2019 · HL · contact PI
Gene Transfer To Treat Heart Failure With Preserved Ejection Fraction$0
I01 · FY2019 · VA · contact PI
ShEEP Request for Comprehensive Lab Animal Monitoring System (CLAMS) / Oxy CLAMS$0
IS1 · FY2019 · VA · contact PI
Gene Transfer To Treat Heart Failure With Preserved Ejection Fraction$0
I01 · FY2018 · VA · contact PI
Discovery and Development of Therapeutic Genes for CHF$2,974,646
P01 · FY2017 · HL · contact PI
C1C2 Gene Transfer in CHF$811,017
P01 · FY2017 · HL · contact PI
Urocortin-2 Gene Transfer for CHF: a Paracrine Approach Using Intravenous AAV8$802,500
R42 · FY2017 · HL · contact PI
Translational Systems$652,002
P01 · FY2017 · HL · contact PI
Clinical & Administrative$169,685
P01 · FY2017 · HL · contact PI
Gene Transfer To Treat Heart Failure With Preserved Ejection Fraction$0
I01 · FY2017 · VA · contact PI
Discovery and Development of Therapeutic Genes for CHF$2,976,411
P01 · FY2016 · HL · contact PI
C1C2 Gene Transfer in CHF$811,017
P01 · FY2016 · HL · contact PI
Urocortin-2 Gene Transfer for CHF: a Paracrine Approach Using Intravenous AAV8$802,500
R42 · FY2016 · HL · contact PI
Translational Systems$652,002
P01 · FY2016 · HL · contact PI
Clinical & Administrative$169,684
P01 · FY2016 · HL · contact PI
Discovery and Development of Therapeutic Genes for CHF$2,932,664
P01 · FY2015 · HL · contact PI
C1C2 Gene Transfer in CHF$658,178
P01 · FY2015 · HL · contact PI
Translational Systems$543,943
P01 · FY2015 · HL · contact PI
Clinical & Administrative$197,451
P01 · FY2015 · HL · contact PI
Translational Studies of Paracrine CV Gene Transfer$0
I01 · FY2015 · VA · contact PI
Discovery and Development of Therapeutic Genes for CHF$2,917,776
P01 · FY2014 · HL · contact PI
C1C2 Gene Transfer in CHF$656,051
P01 · FY2014 · HL · contact PI
Translational Systems$541,816
P01 · FY2014 · HL · contact PI
Urocortin-2 Gene Transfer for CHF: a Paracrine Approach Using Intravenous AAV8$240,750
R42 · FY2014 · HL · contact PI
Clinical & Administrative$195,324
P01 · FY2014 · HL · contact PI
Translational Studies of Paracrine CV Gene Transfer$0
I01 · FY2014 · VA · contact PI
Discovery and Development of Therapeutic Genes for CHF$2,972,180
P01 · FY2013 · HL · contact PI
C1C2 Gene Transfer in CHF$805,333
P01 · FY2013 · HL · contact PI
Translational Systems$642,742
P01 · FY2013 · HL · contact PI
Mechanisms of Adenylyl Cyclase Effects in the Heart$333,638
R01 · FY2013 · HL · contact PI
Clinical & Administrative$169,684
P01 · FY2013 · HL · contact PI
Translational Studies of Paracrine CV Gene Transfer$0
I01 · FY2013 · VA · contact PI
Mechanisms of Adenylyl Cyclase Effects in the Heart$350,460
R01 · FY2012 · HL · contact PI
Translational Studies of Paracrine CV Gene Transfer$0
I01 · FY2012 · VA · contact PI
Mechanisms of Adenylyl Cyclase Effects in the Heart$354,000
R01 · FY2011 · HL · contact PI
Translational Studies of AAV Gene Transfer for CHF$346,250
R01 · FY2011 · HL · contact PI
Cardiac Gene Transfer of AC & Mechanisms for Effects$2,364,337
P01 · FY2010 · HL · contact PI
Adenylyl Cyclase Type VI for CHF$858,613
P01 · FY2010 · HL · contact PI
Mechanisms of Adenylyl Cyclase Effects in the Heart$354,000
R01 · FY2010 · HL · contact PI
Translational Studies of AAV Gene Transfer for CHF$346,250
R01 · FY2010 · HL · contact PI
Cardiac Gene Transfer of AC & Mechanisms for Effects$2,322,757
P01 · FY2009 · HL · contact PI
Adenylyl Cyclase Type VI for CHF$837,032
P01 · FY2009 · HL · contact PI
Translational Studies of AAV Gene Transfer for CHF$346,250
R01 · FY2009 · HL · contact PI
Cardiac Gene Transfer of AC & Mechanisms for Effects$2,236,747
P01 · FY2008 · HL · contact PI
Adenylyl Cyclase Type VI for CHF$799,834
P01 · FY2008 · HL · contact PI
Translational Studies of AAV Gene Transfer for CHF$346,250
R01 · FY2008 · HL · contact PI
Mechanisms for Adenylyl Cyclase Effects in the Heart$342,293
R01 · FY2008 · HL · contact PI
Cardiac Gene Transfer of AC & Mechanisms for Effects$2,243,209
P01 · FY2007 · HL · contact PI
Adenylyl Cyclase Type VI for CHF$754,341
P01 · FY2007 · HL · contact PI
Mechanisms for Adenylyl Cyclase Effects in the Heart$342,293
R01 · FY2007 · HL · contact PI
Cardiac Gene Transfer of AC & Mechanisms for Effects$2,311,494
P01 · FY2006 · HL · contact PI
Adenylyl Cyclase Type VI for CHF$707,895
P01 · FY2006 · HL · contact PI
Mechanisms for Adenylyl Cyclase Effects in the Heart$352,517
R01 · FY2006 · HL · contact PI
Gene Therapy:Translating Basic Science to the Clinic$1,741,423
P01 · FY2005 · HL
Mechanisms for Adenylyl Cyclase Effects in the Heart$361,000
R01 · FY2005 · HL
Adenylyl cyclase VIII gene therapy for CHF$290,237
P01 · FY2005 · HL
Gene Therapy:Translating Basic Science to the Clinic$43,320
P01 · FY2005 · HL
Gene Therapy:Translating Basic Science to the Clinic$1,825,063
P01 · FY2004 · HL
Gene Therapy:Translating Basic Science to the Clinic$12,673
P01 · FY2004 · HL
Gene Therapy:Translating Basic Science to the Clinic$1,695,763
P01 · FY2003 · HL
Gene Therapy:Translating Basic Science to the Clinic$8,512
P01 · FY2003 · HL
Gene Therapy:Translating Basic Science to the Clinic$1,649,498
P01 · FY2002 · HL
Adenylyl cyclase VIII gene therapy for CHF$274,916
P01 · FY2002 · HL
Gene Therapy:Translating Basic Science to the Clinic$1,579,670
P01 · FY2001 · HL
Adenylyl cyclase VIII gene therapy for CHF$0
P01 · FY2001 · HL